香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 藥明合聯生物技術有限公司* 執行董事兼首席執行官 李錦才博士 WUXI XDC CAYMAN INC. （於開曼群島註冊成立的有限公司） 藥 明 合 聯 生 物 技 術 有 限 公 司* （股份代號：2268） 董事會會議通告 Wu Xi XDC Cayman Inc.藥明合聯生物技術有限公司*（「本公司」，連同其附屬公 司 ， 統 稱「 本 集 團 」）董 事（「 董 事 」）會（「 董 事 會 」）謹 此 宣 佈 ， 本 公 司 將 於 2026 年 3月23日（ 星期一 ）舉行董事會會議，藉以（ 其中包括 ）審議及批准本集團截至2025 年12月31日止年度的全年業績及其發佈。 承董事會命 香港，2026年1月23日 於本公告日期，本公司董事會包括(i)執行董事李錦才博士、張靖偉先生及席曉捷 先生；(ii)非執行董事陳智勝博士、顧繼 ...

Core Viewpoint - WuXi AppTec (02268) announced the issuance of a total of 2.7517 million shares under its share plan from January 2 to January 21, 2026 [1] Group 1 - The company will issue shares as part of its stock plan [1] - The total number of shares to be issued is 2.7517 million [1] - The issuance period is set from January 2 to January 21, 2026 [1]

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： WuXi XDC Cayman Inc. 藥明合聯生物技術有限公司*（「本公司」） *僅供識別 呈交日期： 2026年1月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | | 02268 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 事件 | | | 已發行股份（ ...

Market Performance - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.29% to 26,487.51 points, the Hang Seng Tech Index down 1.16% to 5,683.44 points, and the National Enterprises Index decreasing by 0.43% to 9,094.76 points [1] - Major technology stocks generally declined, with Alibaba down 0.44%, Tencent down 1.48%, and Xiaomi down 2.74%, while JD.com saw a slight increase of 0.09% [1] - New consumption concept stocks performed well, with Pop Mart rising by 9% and Naixue's Tea increasing by over 4% [1] Corporate News - Codex-B (02487.HK) reported positive top-line results from a Phase III clinical trial for CU-20101, an injectable botulinum toxin type A for moderate to severe glabellar lines [2] - Saint Bella (02508.HK) entered a strategic cooperation framework agreement with Cloudwise Technology to explore the integration of AI and robotics in high-demand home care scenarios [2] Profit Forecasts - China Taiping (00966.HK) expects a net profit increase of approximately 215% to 225% in 2025, compared to 8.432 billion HKD in the previous year [3] - TCL Electronics (01070.HK) anticipates an adjusted net profit of approximately 2.33 billion to 2.57 billion HKD in 2025, representing a growth of 45% to 60% [3] - Jihong Co. (02603.HK) forecasts a net profit of approximately 273 million to 291 million RMB in 2025, a year-on-year increase of 50% to 60% [3] - Guolian Minsheng (01456.HK) expects a net profit of 2.008 billion RMB in 2025, a growth of around 406% [3] - China Railway (00390.HK) reported a new contract amount of 1,165.98 billion RMB in Q4 2025, with a cumulative new contract amount of 2,750.9 billion RMB, a year-on-year growth of 1.3% [3] Sales and Revenue - Shenzhen Holdings (00604.HK) anticipates a total contract sales amount of approximately 13.311 billion RMB in 2025, a decrease of 21.55% [4] - SF Holding (06936.HK) reported a total revenue of 27.339 billion RMB in December from its logistics, supply chain, and international businesses, reflecting a year-on-year growth of 3.41% [5] Institutional Insights - Dongwu Securities noted that the Hong Kong market is in a long-term upward trend but faces short-term challenges, with strong consensus on domestic fundamentals but mixed views on overseas factors [9] - Huaxia Fund emphasized the high sensitivity of the Hong Kong market to corporate earnings and macroeconomic data, suggesting that positive economic surprises could significantly boost market expectations [10] - Tianfeng Securities highlighted that the Hong Kong market has the foundation for a rebound due to valuation recovery and sentiment improvement, but upward momentum may be constrained by high overseas interest rates [10] - Huaxi Securities pointed out that the "AI+" logic is catalyzing valuation optimization in the Hong Kong market, with a focus on internet, technology, and emerging consumption sectors [10]

Market Overview - The Hong Kong stock market indices collectively declined, with the Hang Seng Index falling by 0.29% to 26,487.51 points, the Hang Seng Tech Index down by 1.16%, and the National Enterprises Index decreasing by 0.43% [2][7]. Sector Performance - Technology stocks experienced a mixed performance, with Xiaomi dropping over 2%, Tencent and Meituan down more than 1%, while Baidu saw an increase of nearly 1% [2][7]. - Gold stocks generally rose, with Zijin Mining International increasing by over 5%. Spot gold prices surged, breaking the $4,700 mark, reaching a new historical high [3][8]. - The commercial aerospace sector weakened, with Asia Pacific Satellite falling over 6%. Regulatory comments indicated that the "cooling" of the market is aimed at eliminating bubbles and directing funds towards quality assets [4][9]. - Biopharmaceutical stocks continued to retreat, with WuXi AppTec declining over 3%. Positive developments in the innovative drug sector were noted during the JPM conference, with multinational pharmaceutical companies and biotech firms revealing new pipeline layouts and significant transactions [4][9].

交银国际发表研报指，药明合联发布2025年正面盈利预告，其中收入年增45%以上，得益于订单高速增 长及无锡DP3的投产；毛利大幅增长70%以上，产能利用率和生产效率的提升、有效的成本控制持续推 动利润率改善。订单表现同样亮眼，2025年内，公司共新签70个综合CMC项目，年末综合CMC项目数 达到252个，在全球XDC/XDCCRDMO赛道中位居第一。 根据公司去年业绩预告、更进取的产能扩张计划和管理层最新指引，该行上调公司今明两年净利润预测 2%至3%、提高2027年以后的盈利及资本开支预测。以现金流折现率计，该行上调对其目标价至91港 元，维持"买入"评级及CXO行业首推，看好高景气度赛道龙头的长期高成长确定性。 ...

Core Viewpoint - Morgan Stanley's report indicates that WuXi AppTec (02268) has proposed a full acquisition of Easton Biopharma-B (01875), raising questions among some investors regarding the rationale behind the acquisition [1] Group 1: Financial Performance - In the first half of 2025, Easton Biopharma recorded revenue of 489 million RMB and a profit of 4 million RMB [1] - In comparison, WuXi AppTec's revenue and profit for the same period were 2.701 billion RMB and 74.6 million RMB, respectively [1] Group 2: Business Focus - Historically, Easton Biopharma focused on oncology drugs but has shifted its resources to a CDMO model emphasizing ADC (Antibody-Drug Conjugates) since the 2020s [1] Group 3: Analyst Rating - Morgan Stanley has rated WuXi AppTec as "Overweight" with a target price of 88 HKD [1]

Core Viewpoint - Morgan Stanley has issued a report indicating that WuXi AppTec (02268) is proposing a full acquisition of Dongyao Pharmaceutical-B (01875), raising questions among some investors regarding the rationale behind the acquisition [1] Group 1: Financial Performance - In the first half of 2025, Dongyao Pharmaceutical is projected to record revenue of 489 million RMB and a profit of 4 million RMB [1] - In comparison, WuXi AppTec's revenue and profit for the same period are expected to be 2.701 billion RMB and 74.6 million RMB, respectively [1] Group 2: Business Focus and Strategy - Historically, Dongyao Pharmaceutical focused on oncology drugs, but has shifted its resources to a CDMO model emphasizing ADC (Antibody-Drug Conjugates) since the 2020s [1] Group 3: Analyst Rating and Target Price - Morgan Stanley has rated WuXi AppTec as "Overweight" with a target price of 88 HKD [1]

Group 1 - China's GDP has surpassed 140 trillion yuan for the first time, with a year-on-year growth of 5.0%, indicating a stable economic performance amidst challenges [1][11] - The growth is driven by strategic emerging industries, with significant contributions from high-tech manufacturing and innovation [1][12] - The production of civilian drones increased by 37.3%, and AI development boosted storage chip production by 22.8%, highlighting the strong momentum of new productive forces [1][12] Group 2 - The cryptocurrency market faced a collective sell-off, with Bitcoin dropping below $92,000 and over 247,000 liquidations occurring within 24 hours [2][13] - Concerns about institutional fund instability, profit-taking, and regulatory uncertainties have pressured the market, revealing vulnerabilities in Bitcoin's inflation hedge narrative [2][13] Group 3 - China's foreign trade reached a total value of 45.47 trillion yuan, growing by 3.8%, with Anhui becoming the ninth province to exceed one trillion in foreign trade [2][14] - Anhui's strong growth of 17.3% is attributed to robust industrial support, particularly in automobile exports [2][14] Group 4 - The Chinese pig farming company Xinwufeng is expected to report a net loss of 700 million to 960 million yuan in 2025, despite selling 5.42 million pigs, which is an increase of over 25% from the previous year [3][15] - The loss is primarily due to a significant decline in pig prices and inventory write-downs [3][15] Group 5 - China XD Electric is positioned as a global leader in transformers, benefiting from increased electricity demand driven by AI development and aging power grids in Europe and the US [3][16] - The company has a unique capability in producing complete sets of power transmission and distribution equipment and has secured multiple major projects [3][16] Group 6 - WuXi AppTec plans to acquire Easton Biopharmaceuticals for up to 2.79 billion Hong Kong dollars, aiming to enhance its capabilities in the ADC drug sector [3][17] - The acquisition reflects WuXi's strong performance and expansion strategy, despite Easton's recent revenue and profit declines [3][17] Group 7 - The semiconductor industry is experiencing a new super cycle, with significant price increases expected for traditional products like DDR4, projected to rise by 50% in Q1 2026 [3][18] - The demand for advanced process products is squeezing mature process capacity, leading to tighter supply in traditional storage chips [3][18] Group 8 - Financial data from multiple provinces indicate a strong increase in household savings, with Zhejiang's per capita savings exceeding 170,000 yuan [6][20] - The trend reflects a "save more, borrow less" behavior among residents, while corporate credit has seen significant growth due to policy support [6][20] Group 9 - The EU's Carbon Border Adjustment Mechanism (CBAM) will significantly impact China's steel industry, with potential costs exceeding 800 yuan per ton for exports to Europe [6][22] - The mechanism requires companies to provide EU-recognized carbon emission data, or face higher default values, pushing Chinese steel companies towards green transformation [6][22]

Core Viewpoint - The commercialization of ADC (Antibody-Drug Conjugates) drugs is reaching a turning point, highlighting a capacity gap in the industry as WuXi AppTec (HK02268) announces a significant acquisition of Easton Biopharma (HK01875) to enhance its production capabilities [1][4]. Group 1: Acquisition Details - WuXi AppTec plans to acquire approximately 773 million shares of Easton Biopharma at a price of HKD 4.000 per share, valuing the total equity at approximately HKD 30.91 billion [2]. - The offer price represents a significant premium of about 99% over the closing price of HKD 2.010 per share on December 22, 2025, and a 114.67% premium over the 30-day average closing price of HKD 1.860 per share [2]. - Easton Biopharma has a limited market presence, often referred to as a "zombie stock," with a typical daily trading volume of less than HKD 1 million [2]. Group 2: Business Synergy - The acquisition is driven by the business synergy between WuXi AppTec and Easton Biopharma, as the latter is one of the earliest developers of ADC drugs in China, although it has faced challenges with its ADC pipeline [3]. - Easton Biopharma's revenue from product sales has been increasing, with projected revenues of RMB 3.04 billion, RMB 6.30 billion, and RMB 8.77 billion for 2022, 2023, and 2024 respectively, indicating a shift towards profitability in 2024 [3]. Group 3: Production Capacity and Strategic Fit - Easton Biopharma possesses a large-scale GMP-compliant production facility and has established an integrated ADC platform, which aligns with WuXi AppTec's strategy to enhance production capacity [4][5]. - The geographical proximity of both companies in the Yangtze River Delta region is crucial for reducing technology transfer risks and achieving operational efficiency [1][5]. - WuXi AppTec anticipates significant growth, projecting a revenue increase of over 45% and a gross profit increase of over 70% for 2025, alongside a substantial rise in adjusted net profit [6].